PMID- 28656707
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 1
DP  - 2018 Jan
TI  - Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus 
      dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in 
      patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
PG  - 113-120
LID - 10.1111/dom.13047 [doi]
AB  - AIMS: To compare the efficacy and safety of dipeptidyl peptidase-4 inhibitors 
      (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) as monotherapy 
      or add-on to metformin (Met) in patients with type 2 diabetes mellitus (T2DM). 
      MATERIALS AND METHODS: PubMed, Embase and ClinicalTrials.gov sites were 
      systematically searched for randomized controlled trials to assess the efficacy 
      and safety of DPP-4is and SGLT-2is in patients with T2DM. Risk ratio (RR) and 
      weighted mean difference (WMD) were used to evaluate outcomes. RESULTS: In the 
      analysis of 25 randomized trials, which involved 14 619 patients, SGLT-2is were 
      associated with a significantly stronger reduction in haemoglobin A1c (HbA1c) 
      (WMD 0.13%, 95% credible interval [CI], 0.04%-0.22%, P = .005) and fasting plasma 
      glucose (FPG) (WMD 0.80 mmol/L, 95% CI, 0.58-1.01 mmol/L, P < .00001) than were 
      DPP-4is. However, no significant difference between the 2 drug categories was 
      found in the risk of hypoglycaemic events (RR, 0.99; 95% CI, 0.78-1.26, P = .92). 
      SGLT-2is plus Met was associated with a more significant decrease in FPG (WMD 
      0.71 mmol/L, 95% CI, 0.43-1.00 mmol/L, P < .00001) than was DPP-4is plus Met. 
      However, no differences were found in the reduction of HbA1c (WMD 0.11%, 95% CI, 
      -0.03%-0.25%, P = .12) or the risk of hypoglycaemic events (RR, 1.02; 95% CI, 
      0.80-1.31, P = .86). CONCLUSIONS: This review revealed that, compared to DPP-4is, 
      SGLT-2is significantly reduced HbA1c, FPG and body weight without increasing the 
      risk of hypoglycaemia in diabetes treatment.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Wang, Zhiying
AU  - Wang Z
AUID- ORCID: 0000-0002-7226-1686
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Sun, Jiahui
AU  - Sun J
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Han, Ruobing
AU  - Han R
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Fan, Dongzhu
AU  - Fan D
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Dong, Xinyi
AU  - Dong X
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Luan, Zenghui
AU  - Luan Z
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Xiang, Rongwu
AU  - Xiang R
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Zhao, Mingyi
AU  - Zhao M
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
FAU - Yang, Jingyu
AU  - Yang J
AD  - Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 
      China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170810
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Membrane Transport Modulators)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Anti-Obesity Agents/adverse effects/therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Drug Resistance
MH  - Drug Therapy, Combination/adverse effects
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemia/chemically induced/prevention & control
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Membrane Transport Modulators/adverse effects/*therapeutic use
MH  - Metformin/*therapeutic use
MH  - Overweight/complications/drug therapy/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - dipeptidyl peptidase-4 inhibitors
OT  - sodium-glucose cotransporter-2 inhibitors
OT  - type 2 diabetes mellitus
EDAT- 2017/06/29 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/06/29 06:00
PHST- 2017/03/25 00:00 [received]
PHST- 2017/06/16 00:00 [revised]
PHST- 2017/06/23 00:00 [accepted]
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/06/29 06:00 [entrez]
AID - 10.1111/dom.13047 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Jan;20(1):113-120. doi: 10.1111/dom.13047. Epub 2017 
      Aug 10.